articleTop 1% cited

Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology · 2006 · Vol. 102(3) · pp. 432–439

Jeffrey G. Bell✉(Riverside Methodist Hospital)Mark F. Brady(Gynecologic Oncology Group)Robert C. Young(Fox Chase Cancer Center)Janice M. Lage(Medical University of South Carolina)Joan L. Walker(University of Oklahoma Health Sciences Center)Katherine Y. Look(Indiana University – Purdue University Indianapolis)G. Scott RoseNick M. Spirtos(University of Nevada, Reno)

View via DOI Publisher page

Ovarian cancer diagnosis and treatment Neuroendocrine Tumor Research Advances Lung Cancer Research StudiesMedicineCarboplatinHazard ratioGynecologic oncologyStage (stratigraphy)Internal medicineConfidence intervalRandomizationChemotherapyCarcinoma

MeSH terms

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinomaDrug Administration ScheduleFemaleHumansMiddle AgedNeoplasm Recurrence, LocalOvarian NeoplasmsProportional Hazards ModelsSurvival AnalysisCarboplatinChemotherapy, AdjuvantPaclitaxel

Funding

National Cancer Institute

Citations

307

FWCI

19.10

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of Oncology · 2013 · 1,110 citations

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

Annals of Oncology · 2019 · 1,130 citations

Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.